Defibrotide - Jazz Pharmaceuticals

Drug Profile

Defibrotide - Jazz Pharmaceuticals

Alternative Names: Defibrotide sodium; Defitelio; Fraction P; JZP-381; Noravid; NS 73; Prociclide

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gentium
  • Developer Fukushima Medical University; Gentium; Jazz Pharmaceuticals plc; Swedish Orphan Biovitrum
  • Class Antithrombotics; Nucleotide aptamers; Polydeoxyribonucleotides
  • Mechanism of Action Angiogenesis inhibitors; Heparanase inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Veno-occlusive disorders
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Veno-occlusive disorders
  • Preclinical Graft-versus-host disease
  • Market Withdrawal Deep vein thrombosis; Thrombosis
  • No development reported Diabetic nephropathies; Multiple myeloma

Most Recent Events

  • 17 Nov 2017 Preclinical development in Graft-versus-host disease (Prevention) is ongoing
  • 17 Nov 2017 Jazz Pharmaceuticals plans a phase II trial for Graft-versus-host disease (Prevention, Adjunctive treatment, In infants, In children, In adolescents, In adults, In the elderly) in January 2018 (NCT03339297)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetic-nephropathies in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top